<DOC>
	<DOCNO>NCT02061397</DOCNO>
	<brief_summary>The purpose research study see simvastatin take safely patient either LAM TSC , already treat everolimus sirolimus . This first step look simvastatin drug may help patient , impact growth survival cell make lung lesion cause problem LAM TSC patient . The study also seek learn simvastatin work , give patient treat everolimus sirolimus , evaluate safety potential benefit patient take 2-drug combination . The primary objective study determine safety simvastatin treatment LAM-S LAM-TS patient stable ( least 3 month ) dose sirolimus everolimus . Secondary objective include : - To assess effect simvastatin force expiratory volume 1 second ( FEV1 ) . - To assess effect simvastatin force vital capacity ( FVC ) . - To assess effect simvastatin diffuse lung capacity ( DLCO ) . - To assess effect simvastatin vascular endothelial growth factor -D ( VEGF-D ) serum level . - To assess effect simvastatin questionnaire- base assessment dyspnea , fatigue , quality life ( QOL ) . - Assess sign clinical benefit .</brief_summary>
	<brief_title>Safety Simvastatin LAM TSC</brief_title>
	<detailed_description>After provide write informed consent , study related tests/procedures do ensure eligibility study . If find eligible , participant give simvastatin start dose 20 mg , take even mouth . If 2 month simvastatin 20 mg dose tolerate , dose simvastatin increase 40 mg even mouth . Doses may adjust need , participant experience side effect simvastatin . The participant 's dose everolimus sirolimus expect change , dose previously tolerate . If side effect occur result combination drug , dosage may adjust study physician ( investigator ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Female , age 18 old clinically definitive diagnosis ( biopsy proven compatible chest CT/MRI scan ) sporadic LAM ( LAMS ) LAM associate TS ( LAMTS ) . Treated stable ( least 3 month ) dose sirolimus everolimus Negative pregnancy test ( woman child bear potential ) screening . Women childbearing potential must use barrier , medically acceptable contraceptive precaution . Signed date informed consent . Age &lt; 18 year Known allergy simvastatin currently take simvastatin , therapy medication class simvastatin within past 30 day . Allergy sirolimus everolimus . Current use sirolimus everolimus investigational drug TSC LAM within past 30 day . Use estrogen contain medication , include birth control pill , within 30 day prior enrollment . Treatment drug know metabolic interaction statin drug ( e.g . cytochrome P450 3A4 metabolism ) , include ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , azithromycin , niacin ( nicotinic acid ) , digoxin , warfarin , sildenafil use strong CYP3A4 inhibitor include gemfibrozil , cyclosporine , danazol , verapamil , diltiazem , dronedarone . amiodarone , amlodipine , ranolazine . Participation another clinical study ( y ) investigational treatment drug within 30 day prior screen visit . Amiodarone ; within past 30 day . Significant dysfunction liver ( ALT &gt; 2 time upper limit normalULN ) , kidney ( serum creatinine &gt; 1.5 time ULN ) , blood ( leucopenia ( ANC &lt; 2000 ) , anemia , Hgb &lt; 11 gm/dl ) . History inflammatory muscle disease myopathy . Bleeding diathesis anticoagulant therapy . Uncontrolled hyperlipidemia diabetes . Pregnant , breast feeding , plan become pregnant within next 6 month Inadequate contraception ( must agree barrier method ) History organ transplant . Active transplant list . Severe uncontrolled medical condition would cause unacceptable safety risk compromise compliance protocol . Unstable seizure ( recent change pattern antiepileptic ) . Mental illness cognitive deficit precluding inform consent.. Inability attend schedule clinic visit comply study procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>lymphangioleiomyomatosis ( LAM )</keyword>
	<keyword>tuberous sclerosis complex ( TSC )</keyword>
	<keyword>simvastatin</keyword>
	<keyword>sirolimus</keyword>
	<keyword>everolimus</keyword>
</DOC>